Targeted screening for third-generation cephalosporin-resistant Enterobacteriaceae carriage among patients admitted to intensive care units: A quasi-experimental study

Critical Care

Volumn 19, Issue 1, 2015, Pages

  Dananché, Cédric ^a   Bénet, Thomas ^a,b   Allaouchiche, Bernard ^a   Hernu, Romain ^a   Argaud, Laurent ^a   Dauwalder, Olivier ^c   Vandenesch, François ^c   Vanhems, Philippe ^a,b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

^c HOSPICES CIVILS DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ADULT; AGED; ARTICLE; CEPHALOSPORIN RESISTANT ENTEROBACTERIACEAE; COMPARATIVE STUDY; CONTROLLED STUDY; ENTEROBACTERIACEAE; FEMALE; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATIENT TRANSPORT; PRIORITY JOURNAL; QUASI EXPERIMENTAL STUDY; RECTAL SWAB; SCREENING; SMEAR; ANTIBIOTIC RESISTANCE; CROSS INFECTION; DIAGNOSIS; DRUG EFFECTS; HETEROZYGOTE; INFECTION CONTROL; ISOLATION AND PURIFICATION; MASS SCREENING; MICROBIOLOGY; PROCEDURES; RECTUM;

ANTI-BACTERIAL AGENTS; CARRIER STATE; CEPHALOSPORIN RESISTANCE; CEPHALOSPORINS; CROSS INFECTION; ENTEROBACTERIACEAE; HUMANS; INCIDENCE; INFECTION CONTROL; INTENSIVE CARE UNITS; MASS SCREENING; RECTUM;

EID: 84924255280     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-015-0754-7     Document Type: Article

References (44)

1. Paterson DL. Resistance in Gram-negative bacteria: Enterobacteriaceae. Am J Infect Control. 2006;34:S20-8. discussion S64-S73.
2. Valverde A, Coque TM, Sánchez-Moreno MP, Rollán A, Baquero F, Cantón R. Dramatic increase in prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol. 2004;42:4769-75.
3. Gagliotti C, Balode A, Baquero F, Degener J, Grundmann H, Gür D, et al. Escherichia coli and Staphylococcus aureus: bad news and good news from the European Antimicrobial Resistance Surveillance Network (EARS-Net, formerly EARSS), 2002 to 2009. Euro Surveill. 2011;16:19819. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19819 . Accessed 6 Feb 2015.
4. Arnaud I, Jarlier V, groupe de travail BMR-Raisin; Institut de veille sanitaire. Surveillance of multidrug resistant bacteria in French healthcare facilities: BMR-Raisin network-results 2012. Saint-Maurice, France: Institut de veille sanitaire; 2014. French. http://www.invs.sante.fr/Publications-et-outils/Rapports-et-syntheses/Maladies-infectieuses/2014/Surveillance-des-bacteries-multiresistantes-dans-les-etablissements-de-sante-francais . Accessed 6 Feb 2015.
5. Lucet JC. Birgand G [Multiply resistant Gram-negative bacteria: where do we go from here?]. J Antiinfect. 2011;13:122-32. doi:10.1016/j.antinf.2011.03.006. French.
6. Pitout JD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159-66.
7. Khan AS, Dancer SJ, Humphreys H. Priorities in the prevention and control of multidrug-resistant Enterobacteriaceae in hospitals. J Hosp Infect. 2012;82:85-93.
8. Lucet JC, Decré D, Fichelle A, Joly-Guillou ML, Pernet M, Deblangy C, et al. Control of a prolonged outbreak of extended-spectrum β-lactamase-producing Enterobacteriaceae in a university hospital. Clin Infect Dis. 1999;29:1411-8.
9. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657-86.
10. Siegel JD, Rhinehart E, Jackson M, Chiarello L, Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control. 2007;35:S165-93.
11. Siegel JD, Rhinehart E, Jackson M, Chiarello L, Healthcare Infection Control Practices Advisory Committee. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings. Am J Infect Control. 2007;35:S65-164.
12. Goddard S, Muller MP. The efficacy of infection control interventions in reducing the incidence of extended-spectrum β-lactamase-producing Enterobacteriaceae in the nonoutbreak setting: a systematic review. Am J Infect Control. 2011;39:599-601.
13. Lowe C, Katz K, McGeer A, Muller MP. Disparity in infection control practices for multidrug-resistant Enterobacteriaceae. Am J Infect Control. 2012;40:836-9.
14. Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014;20:1-55.
15. Gardam MA, Burrows LL, Kus JV, Brunton J, Low DE, Conly JM, et al. Is surveillance for multidrug-resistant Enterobacteriaceae an effective infection control strategy in the absence of an outbreak? J Infect Dis. 2002;186:1754-60.
16. Thouverez M, Talon D, Bertrand X. Control of Enterobacteriaceae producing extended-spectrum β-lactamase in intensive care units: rectal screening may not be needed in non-epidemic situations. Infect Control Hosp Epidemiol. 2004;25:838-41.
17. Schnell D, Kouatchet AT, Lécuyer H, Talbi A, Descamps P, Nassif X, et al. Is extended-spectrum β-lactamase-producing Escherichia coli rectal carriage at hospital admission predictable? Risk factors at hospital admission. J Hosp Infect. 2010;76:178-80.
18. Meyer E, Serr A, Schneider C, Utzolino S, Kern WV, Scholz R, et al. Should we screen patients for extended spectrum β lactamase-producing Enterobacteriaceae in intensive care units? Infect Control Hosp Epidemiol. 2009;30:103-5.
19. Ben-Ami R, Schwaber MJ, Navon-Venezia S, Schwartz D, Giladi M, Chmelnitsky I, et al. Influx of extended-spectrum β-lactamase-producing Enterobacteriaceae into the hospital. Clin Infect Dis. 2006;42:925-34.
20. Friedmann R, Raveh D, Zartzer E, Rudensky B, Broide E, Attias D, et al. Prospective evaluation of colonization with extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae among patients at hospital admission and of subsequent colonization with ESBL-producing Enterobacteriaceae among patients during hospitalization. Infect Control Hosp Epidemiol. 2009;30:534-42.
21. Azim A, Dwivedi M, Rao PB, Baronia AK, Singh RK, Prasad KN, et al. Epidemiology of bacterial colonization at intensive care unit admission with emphasis on extended-spectrum β-lactamase- and metallo-β-lactamase-producing Gram-negative bacteria - an Indian experience. J Med Microbiol. 2010;59:955-60.
22. Harris AD, McGregor JC, Johnson JA, Strauss SM, Moore AC, Standiford HC, et al. Risk factors for colonization with extended-spectrum β-lactamase-producing bacteria and intensive care unit admission. Emerg Infect Dis. 2007;13:1144-9.
23. Razazi K, Derde LPG, Verachten M, Legrand P, Lesprit P, Brun-Buisson C. Clinical impact and risk factors for colonization with extended-spectrum β-lactamase-producing bacteria in the intensive care unit. Intensive Care Med. 2012;38:1769-78.
24. Centre de coordination de la lutte contre les infections associées aux soins, Réseau REA-RAISIN: Surveillance des infections nosocomiales dans les réanimations adultes. http://www.cclinparisnord.org/REACAT/REA.htm . Accessed 6 Feb 2015.
25. Januel JM, Harbarth S, Allard R, Voirin N, Lepape A, Allaouchiche B, et al. Estimating attributable mortality due to nosocomial infections acquired in intensive care units. Infect Control Hosp Epidemiol. 2010;31:388-94.
26. Bénet T, Allaouchiche B, Argaud L, Vanhems P. Impact of surveillance of hospital-acquired infections on the incidence of ventilator-associated pneumonia in intensive care units: a quasi-experimental study. Crit Care. 2012;16:R161.
27. Centers for Disease Control and Prevention, Healthcare Infection Control Practices Advisory Committee (HIPAC). 2007 Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. Part III: precautions to prevent transmission of infectious agents. http://www.cdc.gov/hicpac/2007IP/2007ip_part3.html . Accessed 6 Feb 2015.
28. Comité technique des infections nosocomiales et des infections liées aux soins (CTINILS). Définition des infections associées aux soins. May 2007. http://www.sante.gouv.fr/IMG/pdf/rapport_vcourte.pdf . Accessed 6 Feb 2015.
29. European Center for Disease Prevention and Control (ECDC). European surveillance of healthcare-associated infections in intensive care units. HAIICU Protocol v1.01 STANDARD and LIGHT. December 2010. http://www.ecdc.europa.eu/en/aboutus/calls/Procurement%20Related%20Documents/5_ECDC_HAIICU_protocol_v1_1.pdf . Accessed 6 Feb 2015.
30. Leonhardt KK, Yakusheva O, Phelan D, Reeths A, Hosterman T, Bonin D, et al. Clinical effectiveness and cost benefit of universal versus targeted methicillin-resistant Staphylococcus aureus screening upon admission in hospitals. Infect Control Hosp Epidemiol. 2011;32:797-803.
31. Weber SG, Huang SS, Oriola S, Huskins WC, Noskin GA, Harriman K, et al. Legislative mandates for use of active surveillance cultures to screen for methicillin resistant Staphylococcus aureus and vancomycin resistant Enterococci: position statement from the joint SHEA and APIC Task Force. Infect Control Hosp Epidemiol. 2007;28:249-60.
32. Harris AD, Kotetishvili M, Shurland S, Johnson JA, Morris JG, Nemoy LL, et al. How important is patient-to-patient transmission in extended-spectrum β-lactamase Escherichia coli acquisition. Am J Infect Control. 2007;35:97-101.
33. Harris AD, Perencevich EN, Johnson JK, Paterson DL, Morris JG, Strauss SM, et al. Patient-to-patient transmission is important in extended-spectrum β-lactamase-producing Klebsiella pneumoniae acquisition. Clin Infect Dis. 2007;45:1347-50.
34. Harris AD, McGregor JC, Furuno JP. What infection control interventions should be undertaken to control multidrug-resistant Gram-negative bacteria? Clin Infect Dis. 2006;43:S57-61.
35. Vodovar D, Marcadé G, Raskine L, Malissin I, Mégarbane B. Enterobacteriaceae producing extended spectrum β-lactamase: epidemiology, risk factors, and prevention. Rev Med Interne. 2013;34:687-93. French.
36. Conterno LO, Shymanski J, Ramotar K, Toye B, Zvonar R, Roth V. Impact and cost of infection control measures to reduce nosocomial transmission of extended-spectrum β-lactamase-producing organisms in a non-outbreak setting. J Hosp Infect. 2007;65:354-60.
37. Huang SS, Septimus E, Kleinman K, Moody J, Hickok J, Avery TR, et al. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med. 2013;368:2255-65.
38. Troché G, Joly L, Guibert M, Zazzo J. Detection and treatment of antibiotic resistant bacterial carriage in a surgical intensive care unit: a 6 year prospective survey. Infect Control Hosp Epidemiol. 2005;26:161-5.
39. Biehl LM, Schmidt-Hieber M, Liss B, Cornely OA, Vehreschild MJGT. Colonization and infection with extended spectrum β-lactamase producing Enterobacteriaceae in high-risk patients: review of the literature from a clinical perspective. Crit Rev Microbiol. In press. doi:10.3109/1040841X.2013.875515.
40. Lowe CF, Katz K, McGeer AJ, Muller MP, for the Toronto ESBL Working Group. Efficacy of admission screening for extended-spectrum β-lactamase producing Enterobacteriaceae. PLoS One. 2013;8:e62678.
41. Harris AD, Bradham DD, Baumgarten M, Zuckerman IH, Fink JC, Perencevich EN. The use and interpretation of quasi-experimental studies in infectious diseases. Clin Infect Dis. 2004;38:1586-91.
42. Harris AD, Lautenbach E, Perencevich E. A systematic review of quasi-experimental study designs in the fields of infection control and antibiotic resistance. Clin Infect Dis. 2005;41:77-82.
43. Shardell M, Harris AD, El-Kamary SS, Furuno JP, Miller RR, Perencevich EN. Statistical analysis and application of quasi experiments to antimicrobial resistance intervention studies. Clin Infect Dis. 2007;45:901-7.
44. Courpon-Claudinon A, Lefort A, Panhard X, Clermont O, Dornic Q, Fantin B, et al. Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features. Clin Microbiol Infect. 2011;17:557-65.